ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1638

Anti-Dense Fine Speckled 70 Antibodies:  Long-Term Followup Study of Clinical Associations in a US Laboratory Patient Population

Mark H. Wener1 and Kathleen Hutchinson2, 1Rheumatology & Lab Med, University of Washington, Seattle, WA, 2Lab Medicine, University of Washington, SEATTLE, WA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ANA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose

The recently recognized nuclear dense fine speckled immunofluorescence (IF) ANA pattern is associated with antibodies to the dense fine speckled 70 (DFS70) antigen.   Presence of antiDFS70 may identify populations with a low prevalence of autoimmune rheumatic disease.  Long-term followup  evaluation of the associations of antiDFS70 is limited. 

Methods

Serum samples sent for ANA tests to our clinical laboratory were tested for ANA by a multiplex bead assay and HEp2 IF in 2011.   Specimens with a positive IF ANA but negative for tested ANA subsets were identified.  Randomly selected samples from that population were tested using a commercial anti-DFS70 ELISA and chart reviews were done on positive samples.  Long-term followup based on chart review was performed in 2014. 

Results

Long-term followup (at least 6 months, range 6 to 36 months) was available for 32 patients.  No definitive autoimmune rheumatic disease was diagnosed in any patient.  One patient was treated with hydroxychloroquine for possible undifferentiated connective tissue disease, in part because of the persistent positive ANA, arthralgias, and hearing problems felt most likely to be due to otosclerosis.  One patient was diagnosed with celiac disease, one patient had idiopathic glomerulosclerosis with other features of autoimmune disease, and one patient had idiopathic pulmonary fibrosis requiring lung transplant.  Two patients developed multiple sclerosis.  Common clinical symptoms were arthralgias and/or myalgias (7/32) including 4 diagnosed with fibromyalgiaAsthma was found in 3 patients, irritable bowel syndrome in 3 patients, and headaches (including migraines) in 5.  Two patients were diagnosed with depression.  No chronic atopic dermatitis, cystitis or malignancy (diagnoses previously reported with antiDFS70) were found.

Conclusion

None of our subjects had an identified autoimmune rheumatic disease on long-term followup.  From this U.S. population, although small, we provide additional support for the proposal that sera with only DFS70 antibodies may help identify patients who do not have a rheumatologic disease despite a positive ANA IF test.


Disclosure:

M. H. Wener,

Inova Diagnostics, Inc.,

9;

K. Hutchinson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-dense-fine-speckled-70-antibodies-long-term-followup-study-of-clinical-associations-in-a-us-laboratory-patient-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology